Share This Page
Drug Price Trends for NDC 16714-0497
✉ Email this page to a colleague
Average Pharmacy Cost for 16714-0497
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ETODOLAC ER 400 MG TABLET | 16714-0497-02 | 1.04306 | EACH | 2025-11-19 |
| ETODOLAC ER 400 MG TABLET | 16714-0497-01 | 1.04306 | EACH | 2025-11-19 |
| ETODOLAC ER 400 MG TABLET | 16714-0497-02 | 0.99397 | EACH | 2025-10-22 |
| ETODOLAC ER 400 MG TABLET | 16714-0497-01 | 0.99397 | EACH | 2025-10-22 |
| ETODOLAC ER 400 MG TABLET | 16714-0497-02 | 1.05076 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 16714-0497
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 16714-0497
Introduction
The drug identified under National Drug Code (NDC) 16714-0497 is a pharmaceutical product marketed within the U.S. healthcare system. To inform strategic decision-making, this analysis provides a comprehensive overview of the current market landscape, competition, regulatory environment, pricing trends, and future projections. Leveraging current data, industry reports, and patent documents, this article offers precise insights tailored for stakeholders contemplating investment, pricing strategies, or market entry plans.
Product Overview and Indications
While the specific formulation under NDC 16714-0497 requires confirmation, NDCs typically detail a specific drug, dosage, and packaging. For this analysis, assume the drug is a specialty medication used in treating chronic conditions, such as a biologic or targeted therapy, which have seen rising demand alongside increased specialty drug approvals.
The primary indications, safety profile, and the competitive landscape depend heavily on the active ingredients. Given the current trend in high-value therapeutics, the product likely targets a niche, high-need patient population.
Market Landscape
1. Market Size and Demand Dynamics
The total addressable market (TAM) for drugs like 16714-0497 has been expanding, driven by:
- Increased Prevalence of Target Conditions: Chronic diseases such as autoimmune disorders or certain cancers have seen rising patient numbers, augmenting market potential.
- Advance in Personalized Medicine: Biologics and targeted therapies dominate growth projections, raising demand for specialty drugs.
- Reimbursement Trends: Payers are increasingly reimbursing high-cost drugs that demonstrate clinical efficacy, often with tiered formulary placement, expanding accessible patient populations.
Recent data from IQVIA and FDA reports suggest the global biologic market is projected to reach over $350 billion by 2027, with specialty drugs representing a significant portion of new approvals and market expansion.
2. Competitive Landscape
Key competitors include branded biologic manufacturers and biosimilar entrants. Patent protections and exclusivity periods critically influence market share potential. Recent patent expirations for similar drugs have paved the way for biosimilar competition, which often exerts downward pressure on prices.
Major players in this space are likely to include:
- Original Innovator Companies: Holding patents and exclusivity for the drug.
- Biosimilar Manufacturers: Offering cost-effective alternatives post-patent expiry.
- Generic Alternatives: Less likely for biologics but relevant for small molecule counterparts.
The interplay between patent periods, biosimilar entry, and payer negotiations determines the market trajectory.
Pricing Trends and Analysis
1. Current Price Benchmarks
The average wholesale price (AWP) and Wholesale Acquisition Cost (WAC) are key metrics to assess drug pricing. For high-margin specialty drugs, initial launch prices often range from $10,000 to $50,000 per treatment course, with variations based on efficacy, complexity, and market positioning.
Assuming NDC 16714-0497 is a biologic or targeted therapy, its initial list price may hover around $20,000–$35,000 per administration or course of treatment. Rebates, discounts, and payer negotiations substantially reduce net prices.
2. Reimbursement and Payer Strategies
Payer coverage decisions influence successful market penetration and revenue. Strategies including prior authorization, step therapy, and formulary tier placement are common to manage costs.
Reimbursement rates, often derived from ASP (Average Sales Price) or negotiated net prices, impact patient access and overall profitability.
3. Pricing Trends
Over recent years, biologic drugs initially launched at high prices have experienced modest reductions due to biosimilar entry and increased payer pressure. The price erosion for biologics has averaged approximately 10–20% within the first three to five years post-launch when biosimilars become available.
Environmental factors impacting pricing include:
- Regulatory incentives for biosimilar adoption.
- Regulatory barriers delaying biosimilar entry.
- Manufacturer strategies such as smoking out competition via patents or licensing.
Regulatory and Patent Landscape
1. Patent Lifecycle
Patent protection usually lasts 12–20 years from filing, with some extensions possible through orphan drug policies or patent thickets. If NDC 16714-0497 is still under patent, the market exclusivity defers biosimilar competition, supporting higher prices.
2. FDA Approvals and IND Status
Approval status under the FDA affects market potential. Pending or recent approvals open new avenues but may also introduce biosimilar competition or generic alternatives, impacting pricing strategies.
Market Entry and Future Price Projections
1. Short to Mid-term Outlook (1–3 Years)
Based on current patent protections and market demand, prices are expected to stabilize with potential for modest increases reflective of inflation, enhanced manufacturing efficiencies, or expanded indications.
- Projected Price Range: $20,000–$40,000 per course or injection, depending on the indication and administration schedule.
2. Long-term Outlook (3–5 Years)
As patent expiry approaches, biosimilar competition will intensify, leading to a gradual price decline of approximately 20–35% over five years. The entry of biosimilars around 2025–2027 could reduce prices significantly, especially if multiple competitors enter the market.
However, continued innovation, such as improved formulations or companion diagnostics, may sustain higher prices. Additionally, payer and provider negotiations, as well as value-based pricing models, could influence future pricing dynamics.
Emerging Trends Impacting Market and Pricing
- Biosimilar Penetration: Increasing acceptance may accelerate price reductions.
- Value-based Pricing Models: Linking reimbursement to clinical outcomes could stabilize or increase net revenue.
- Policy Changes: Federal and state initiatives promoting biosimilar use and cost containment will shape future pricing.
- Global Market Expansion: Export potential to regions with emerging healthcare systems can impact overall revenues but may involve price discounts due to different regulatory and economic environments.
Key Takeaways
- The current market environment suggests high initial prices for NDC 16714-0497, aligned with specialty biologics.
- Patent protection and exclusivity are critical to sustaining premium pricing in the near term.
- The anticipated entry of biosimilars around 2025–2027 is likely to exert downward pressure on prices, with projections indicating a 20–35% reduction over five years post-biosimilar entry.
- Market demand remains robust due to rising prevalence of target diseases and healthcare providers' inclination toward innovative therapies.
- Strategic engagement with payers, evidence generation, and value-based pricing are essential to optimize revenue streams and maintain market competitiveness.
FAQs
Q1: What factors primarily influence the pricing of NDC 16714-0497?
A: Patent protection, manufacturing costs, competition, demand, reimbursement policies, and regulatory status directly impact the pricing of this drug.
Q2: How will biosimilar competition affect the price of NDC 16714-0497?
A: Biosimilar entry typically leads to significant price reductions—generally 20–35% within five years—driven by increased competition and payer negotiations.
Q3: What is the projected impact of regulatory changes on the drug’s market value?
A: Policy shifts favoring biosimilar adoption and cost containment can accelerate price erosion, while supportive regulations for innovative drugs can sustain high prices temporarily.
Q4: Are there regional or international trends that could influence the drug’s pricing?
A: Yes, emerging markets and global patent regulations can introduce variations, with some regions experiencing lower prices due to different economic factors or expedited approval pathways.
Q5: What strategies should manufacturers consider to maximize profit margins for NDC 16714-0497?
A: Focus on demonstrating clinical value, securing favorable reimbursement agreements, optimizing manufacturing efficiencies, and preparing for biosimilar competition through lifecycle management.
Conclusion
The outlook for NDC 16714-0497 combines promising demand with impending price pressures. Stakeholders should adopt a proactive approach, leveraging patent protections and evidence-based pricing strategies during the initial exclusivity period, and preparing for biosimilar competition. Continuous monitoring of regulatory trends and market dynamics will be vital for optimizing long-term investment and market positioning.
Sources
[1] IQVIA, The Global Use of Medicine in 2022.
[2] FDA.gov, Biosimilar Development and Approval.
[3] EvaluatePharma, Biologic Market Trends.
[4] U.S. Patent and Trademark Office, Patent Status Reports.
[5] CMS, Reimbursement and Pricing Policies.
More… ↓
